Source: Program and Abstracts. Conference titles: Internacional Symposium on Ocular Pharmacology and Therapeutics(ISOPT). Unidade: FMRP
Assunto: EDEMA MACULAR CISTOIDE (TRATAMENTO)
ABNT
PACCOLA, L. et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema. 2008, Anais.. Budapest: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 2008. . Acesso em: 02 maio 2024.APA
Paccola, L., Costa, R. A., Folgosa, M. S., Barbosa, J. C., Scott, I. U., & Jorge, R. (2008). Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema. In Program and Abstracts. Budapest: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.NLM
Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema. Program and Abstracts. 2008 ;[citado 2024 maio 02 ]Vancouver
Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema. Program and Abstracts. 2008 ;[citado 2024 maio 02 ]